Researcher Spotlight: Brian Sworder, MD, PhD Stanford University School of Medicine Chimeric antigen receptor (CAR) T cells have shown to be incredibly beneficial for patients with lymphoma who have relapsed after chemotherapy. Unfortunately, however, several patients will still go on to relapse…
Researcher Spotlight: Coraline Mlynarczyk, PhD Joan & Sanford I. Weill Medical College of Cornell University Diffuse Large B Cell Lymphoma (DLBCL) is a heterogenous B-cell malignancy, with each patient presenting with a heavy and diverse burden of alterations in their DNA. Therefore,…
Researcher Spotlight: Rossella Marullo, MD, PhD Joan & Sanford I. Weill Medical College of Cornell University Two genomic studies revealed that 8 to 16 percent of diffuse large B-cell lymphoma (DLBCL) patients harbor loss-of-function mutations in the gene TOX (TOXLOF). TOX is…
Researcher Spotlight: Arushi Khurana, M.B.B.S Mayo Clinic, Rochester, MN More than two-thirds of the newly diagnosed Diffuse large B-cell lymphoma (DLBCL) patients are excluded from participating in clinical trials, without considering the structural and attitudinal barriers that preclude clinical trial participation. Over…
Researcher Spotlight: David A. Bond, MD The Ohio State University Comprehensive Cancer Center Arthur G. James Cancer Hospital Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL). Since DLBCL can advance quickly, it usually requires…
Researcher Spotlight: Elisa Mandato, PhD DANA-FARBER CANCER INSTITUTE Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL) and the most common hematologic malignancy in the United States. Dr. Mandato’s LRF research project will involve developing…
Researcher Spotlight: Hannah Isles, PhD Weill Cornell Medicine Diffuse large B-cell lymphoma (DLBCL) is an aggressive form of non-Hodgkin lymphoma (NHL). The recentidentification of DLBCL patient subgroups featuring distinct DNA mutation profiles have provided researchers with new opportunities to treat…
Researcher Spotlight: Yong Gu Lee, PhD The Trustees of the University of Pennsylvania Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL) and is the most common hematologic malignancy in the US. The prognosis…
Researcher Spotlight: Alexia Martinez de Paz, PhD Joan & Sanford I. Weill Medical College of Cornell University Cell-fate transitions (a biological process in which the function of a cell gets specialized, reprogrammed, or altered) during the germinal center (GC) reaction…
Researcher Spotlight: Laurianne Scourzic, PhD Joan & Sanford I. Weill Medical College of Cornell University Many B-cell lymphoma patients are resistant to, or relapse after, treatment. While researchers have demonstrated the causal role of cancer stem cells in the relapsing…